Trillium Therapeutics
0
0
+€0,00+0% 00:00 Hari ini
Statistik
Tertinggi hari ini
-
Terendah hari ini
-
Tertinggi 52M
-
Terendah 52M
-
Volume
-
Vol. rata2
-
Kap. pasar
0
Rasio P/E
-
Imbal hasil dividen
-
Dividen
-
Pesaing
Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Tentang
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Tampilkan lebih banyak
CEO
Dr. Jan Skvarka
Karyawan
33
Negara
Kanada
ISIN
CA89620X5064
Pencatatan
0 Komentar
Bagikan pendapatmu
FAQ
Apa simbol saham Trillium Therapeutics?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Muenchen, saham Trillium Therapeutics diperdagangkan dengan simbol R5WP.MU.
Berapa jumlah karyawan Trillium Therapeutics?▼
Per 2 November 2026, perusahaan memiliki 33 karyawan.
Trillium Therapeutics berada di sektor apa?▼
Trillium Therapeutics beroperasi di sektor Kesehatan & Kebugaran.
Kapan Trillium Therapeutics menyelesaikan split saham?▼
Trillium Therapeutics belum melakukan split saham baru-baru ini.
Di mana kantor pusat Trillium Therapeutics?▼
Kantor pusat Trillium Therapeutics berlokasi di Mississauga, Kanada.